BY13

BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR) ) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636) . BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model[1]. Pink: SRC-3 ligand (SI-2) (HY-101447) ; Blue: CRBN ligase ligand (HY-41547) ; Black: linker (HY-176226)

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Estrogen Receptor/ERR; PROTACs; Src

Related Pathways

Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Smiles

C/C(C1=NC=CC=C1)=N\NC2=NC(C=CC=C3)=C3N2C4CN(C4)C5CCN(CC5)C6=CC=CC7=C6C(N(C7=O)C8C(NC(CC8)=O)=O)=O

Molecular Formula

C35H35N9O4

Molecular Weight

645.71

References & Citations

[1]Liang J, et al. Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer. J Med Chem. 2025 Jun 12; 68 (11) :11516-11542.